ConductScience.org, home

Comparison · NCT00465738-98751bf4

incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Responder in Ashworth Scale (Thumb Flexors) at Follow up - Full Analysis Set

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Responder in Ashworth Scale (Thumb Flexors) at Follow up - Full Analysis Set. Trial comparisons, record NCT00465738-98751bf4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00465738-98751bf4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.60.4230.754wilson
Risk in group 20.3910.2220.592wilson
Risk difference, group 1 minus group 20.209-0.05890.438newcombe hybrid score
Risk ratio, group 1 over group 21.530.8522.76log
Odds ratio, group 1 over group 22.330.7687.09log
Number needed to treat, for one more participant with the outcome on incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL than on incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL4.79from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL1830OG000
Group 2incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL923OG001

Outcome

Type
SECONDARY
Title
Responder in Ashworth Scale (Thumb Flexors) at Follow up - Full Analysis Set
Description
Response is defined as an improvement of at least one point in the Ashworth Scale for the treated muscle group from baseline visit.
Time frame
follow up visit, between week 12 and week 20
Population
Analysis is based on Full Analysis Set, defined as all randomized subjects who received at least one dose of study drug. Missing values were not imputed.

Source ClinicalTrials.gov

Trial

Title
IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity
NCT number
NCT00465738
Phases
PHASE3
Conditions
Upper Limb Spasticity
Interventions
incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kD), free from complexing proteins")
Lead sponsor
Merz Pharmaceuticals GmbH
Results first posted
2010-12-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00465738-98751bf4